Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Meditoxin vs Botox in Healthy Volunteers
NCT03317717Phase 1Completed
- Sponsor
- Medytox Inc.
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Meditoxin in benign essential blepharospasm (BEB), glabellar lines and Spasticity (5 arms), sponsored by Medytox Inc. Primary endpoint: Compound Muscle Action Potential amplitude of the Extensor Digitorum Brevis muscle at Day 90. Started Oct 2017; status: completed.
02
Drugs
Meditoxin
03
Conditions
benign essential blepharospasm (BEB)glabellar linesSpasticity
Beyond the preview
Go deeper on NCT03317717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317717.